biomolecules

IMPACT FACTOR 5.5 | Indexed in: PubMed | CITESCORE 8.3

an Open Access Journal by MDPI

Advances in Cancer Therapy Resistance

Guest Editor:

Dr. Majid Momeny
Department of Hematologic Malignancies Translational Science, City of Hope, Monrovia, CA, USA

Deadline for manuscript submissions:
30 June 2024

Message from the Guest Editor

Drug resistance is the main therapeutic obstacle to developing cancer cures and dampens the clinical efficacy of a wide range of anti-cancer therapies, such as radiation, cytotoxic chemotherapies, molecular targeted therapies and immune checkpoint inhibitors. Although combination therapy works well to overcome resistance to single-agent treatments in certain human malignancies, de novo and acquired resistance to combination therapies is common, especially in patients with metastatic disease, preempting the initial success of combinational therapies and resulting in disease relapse. Therefore, a deep apprehension of the molecular mechanisms underlying cancer therapy resistance is necessary to improve current therapies and pave the way for novel and more effective future cancer treatments. In this Special Issue, the latest findings on the distribution of genetic, epigenetic and microenvironmental mediators of cancer therapy resistance will be outlined. Novel treatment methods for overcoming therapy failure in in vitro, in vivo and preclinical models are of particular interest. Research articles, reviews and communications will all be considered for publication in this Special Issue.

biomolecules

IMPACT FACTOR 5.5
Indexed in: PubMed
CITESCORE 8.3

an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen
Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan
Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Biochemistry*)

Contact Us

Biomolecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
𝕏@Biomol_MDPI